NCT01905202 is a Phase 1 clinical trial of Secretrol in Barrett's Esophagus, sponsored by Effexus Pharmaceutical.

Who is sponsoring NCT01905202?

NCT01905202 is sponsored by Effexus Pharmaceutical.

What drugs are being tested in NCT01905202?

Interventions in NCT01905202: Secretrol.

What condition does NCT01905202 study?

NCT01905202 studies Barrett's Esophagus.

Is NCT01905202 still recruiting?

NCT01905202 is currently status unknown. Last updated 1 August 2014.

Last reviewed 2014-08-01 · How we verify

NCT01905202

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus

Status unknown Phase 1 Last updated 1 August 2014

What this trial tests

Phase 1 trial testing Secretrol in Barrett's Esophagus in 13 participants. Status unknown.

Timeline

1 April 2013

Primary endpoint
1 April 2015

Quick facts

Lead sponsor	Effexus Pharmaceutical
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	1 April 2013
Primary completion	1 April 2015
Sites	1 location across United States

Drugs / interventions tested

Secretrol — full drug profile →

Conditions studied

Barrett's Esophagus — all drugs for Barrett's Esophagus →

Sponsor

Effexus Pharmaceutical — full company profile →

Who can join

18 and older, any sex, with Barrett's Esophagus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of patients with adverse events
Time frame: at 6 months

Sponsor's own description

Secretrol administered over a 6 month period to patients with Barrett's Esophagus will be safe and well tolerated. Further, pH control will be evaluated in the distal esophageal mucosa and just below the squamocolumnar junction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Barrett's Esophagus

Currently open trials in the same condition.

NCT06748911 — Navicam for Detection of Barrett's Esophagus · NA · recruiting
NCT05818072 — The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE · NA · recruiting
NCT00590239 — Barrett's Esophagus Related Neoplasia (BERN) Project · recruiting
NCT00288119 — Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01905202 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Effexus Pharmaceutical
Last refreshed: 1 August 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01905202.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing